What is the recommended protocol for cardioversion in atrial fibrillation, including criteria for electrical versus pharmacologic conversion, anticoagulation requirements, and post‑conversion management?

Cardioversion in Atrial Fibrillation

Immediate Cardioversion for Hemodynamic Instability

Proceed immediately with synchronized electrical cardioversion in any patient with hemodynamically unstable atrial fibrillation (ongoing myocardial ischemia, symptomatic hypotension, angina, or acute heart failure) without delaying for anticoagulation, as mortality increases with delayed therapy. 1

• Start IV unfractionated heparin bolus followed by continuous infusion (target aPTT 1.5–2× control) or low-molecular-weight heparin immediately during or after the procedure unless contraindicated 1
• Continue oral anticoagulation (warfarin INR 2.0–3.0 or NOAC) for at least 4 weeks post-cardioversion 1

Anticoagulation Strategy by AF Duration

AF Duration ≥ 48 Hours or Unknown Duration

Prescribe therapeutic anticoagulation for ≥ 3 weeks before and ≥ 4 weeks after cardioversion, regardless of whether electrical or pharmacological methods are used. 2, 1

• NOACs (apixaban, rivaroxaban, dabigatran) are preferred over warfarin because they provide faster onset and comparable safety 1
• Warfarin target: INR 2.0–3.0 2, 1
• This applies to all patients regardless of CHA₂DS₂-VASc score 2

TEE-Guided Approach (Alternative to 3-Week Anticoagulation)

When 3 weeks of anticoagulation is not feasible, perform transesophageal echocardiography to exclude left-atrial or left atrial appendage thrombus. 1

• If no thrombus: start IV heparin or LMWH immediately, proceed with cardioversion, and continue oral anticoagulation for ≥ 4 weeks 1
• If thrombus detected: anticoagulate for 3–4 weeks, repeat TEE, and only cardiovert after thrombus resolution 1

AF Duration < 48 Hours

High stroke risk (CHA₂DS₂-VASc ≥ 2 in men, ≥ 3 in women): administer anticoagulation (heparin, factor Xa inhibitor, or direct thrombin inhibitor) before cardioversion and continue long-term based on risk. 1

• The Canadian Cardiovascular Society permits immediate cardioversion without prior anticoagulation for patients with clear AF onset within 12 hours in the absence of recent stroke/TIA (within 6 months) or in patients with CHADS₂ score < 2 who present after 12 hours but within 48 hours 2
• Low stroke risk (CHA₂DS₂-VASc = 0 in men, = 1 in women): anticoagulation is optional for the procedure itself 1

Important caveat: The European Society of Cardiology permits early cardioversion without TEE in patients with definite AF duration < 48 hours, though this carries a Class IIa recommendation (conflicting evidence but weighted toward recommendation) 2

Electrical Cardioversion Technique

Use R-wave-synchronized direct-current shock with biphasic waveforms, which are more effective than monophasic. 1

Energy Settings

• Biphasic devices: start at 100–150 J, titrate upward to 200 J 1
• Monophasic devices: initial energy 300–360 J 3
• Anterior-posterior electrode placement is recommended 3

Absolute Contraindications (Do Not Cardiovert)

• Digitalis toxicity 1
• Significant hypokalemia 1

Enhancing Success

Pre-treatment with antiarrhythmic drugs (amiodarone, flecainide, ibutilide, propafenone, or sotalol) improves conversion rates and reduces early recurrence. 1

Pharmacological Cardioversion

Agent Selection by Patient Profile

No structural heart disease, no LV dysfunction, no CAD:

• First-line: Flecainide (Class IC), Propafenone (Class IC), Ibutilide (Class III), or Vernakalant (Class III) 1
• Route: oral or IV as indicated 1

Structural heart disease, LV dysfunction, or CAD:

• First-line: Amiodarone (Class III) only 1
• Route: IV or oral (slower conversion) 1

"Pill-in-the-Pocket" Approach

A single oral dose of flecainide or propafenone can terminate AF outside the hospital after prior in-hospital safety testing, provided the patient has no sinus/AV node disease, bundle-branch block, prolonged QT, Brugada syndrome, or structural heart disease. 1

• Mandatory: Beta-blocker or non-dihydropyridine calcium-channel blocker pretreatment to prevent rapid ventricular response if atrial flutter occurs 1

Agents to Avoid

• Digoxin and sotalol are not recommended for acute pharmacological cardioversion because they may be ineffective or pro-arrhythmic 1

Contraindications for Pharmacological Cardioversion

• Sinus node dysfunction 1
• AV-conduction disturbances 1
• QTc > 500 ms 1

Post-Cardioversion Management

Maintain anticoagulation for a minimum of 4 weeks after any cardioversion, then base long-term therapy on CHA₂DS₂-VASc score rather than rhythm status. 1

• Rationale: 98% of thromboembolic events occur within the first 10 days after cardioversion, and atrial mechanical stunning can persist for several weeks 1
• Long-term anticoagulation decisions should be based on the patient's CHA₂DS₂-VASc score and bleeding risk, not on whether sinus rhythm is maintained 1

Consider chronic antiarrhythmic therapy (e.g., amiodarone, sotalol) to sustain sinus rhythm when the risk of recurrence is high. 1

Rate Control Prior to Cardioversion

First-line agents for ventricular rate control: beta-blockers (metoprolol, esmolol), non-dihydropyridine calcium-channel blockers (diltiazem, verapamil), and digoxin (especially in heart-failure patients) 1, 4

• Target heart rate: strict control < 80 bpm for symptomatic patients; lenient control < 110 bpm may be acceptable in asymptomatic patients with preserved LV function 1, 4

Atrial Flutter Considerations

Antithrombotic management for atrial flutter follows the same guidelines as for atrial fibrillation (CHA₂DS₂-VASc-based). 4

• Electrical cardioversion is Class I for stable patients when rhythm-control is desired 4
• Pharmacologic options: oral dofetilide or IV ibutilide are effective (Class IIa) 4
• Catheter ablation is Class I indication for symptomatic or drug-refractory atrial flutter 4